To further explore the role of B2M in mediating resistance, they knocked out the B2M gene in immunocompetent lung cancer mice by CRISPR technology, and the loss of B2M resulted in the resistance to PD-1/PD-L1 blockade [41]. The gene discussed is B2M; the disease is lung carcinoma.